These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10169063)

  • 21. Health technology assessment. The pharmaceutical industry perspective.
    Schubert F
    Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicare payment for new technologies. Can the process be improved despite conflicting goals? An ECRI technology management assessment.
    J Health Care Technol; 1986; 3(1):13-32. PubMed ID: 10300959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biotech pharmaceuticals and biotherapy: an overview.
    Steinberg FM; Raso J
    J Pharm Pharm Sci; 1998; 1(2):48-59. PubMed ID: 10945918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic antibody expression technology.
    Chadd HE; Chamow SM
    Curr Opin Biotechnol; 2001 Apr; 12(2):188-94. PubMed ID: 11287236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Policy formulation and technology assessment.
    Banta HD; Behney CJ
    Milbank Mem Fund Q Health Soc; 1981; 59(3):445-79. PubMed ID: 6792555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 2: coverage.
    Raab GG; Parr DH
    J Am Coll Radiol; 2006 Oct; 3(10):772-7. PubMed ID: 17412167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ['New look' biotechnology].
    de Voogd van der Straaten WA
    Tijdschr Diergeneeskd; 1987 Jan; 112(1):3-8. PubMed ID: 3469783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hybrid and disposable facilities for manufacturing of biopharmaceuticals: pros and cons.
    Ravisé A; Cameau E; De Abreu G; Pralong A
    Adv Biochem Eng Biotechnol; 2009; 115():185-219. PubMed ID: 19623478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacoeconomics of high-cost biotechnology products.
    Dana WJ; Farthing K
    Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Target product selection - where can Molecular Pharming make the difference?
    Paul MJ; Teh AY; Twyman RM; Ma JK
    Curr Pharm Des; 2013; 19(31):5478-85. PubMed ID: 23394563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation and health care decision-making.
    Rutten F
    Health Policy; 1996 Jun; 36(3):215-29. PubMed ID: 10158267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Administrative and research policies required to bring cellular therapies from the research laboratory to the patient's bedside.
    Yim R
    Transfusion; 2005 Oct; 45(4 Suppl):144S-58S. PubMed ID: 16181400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plants as bioreactors for biopharmaceuticals: regulatory considerations.
    Miele L
    Trends Biotechnol; 1997 Feb; 15(2):45-50. PubMed ID: 9081298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease.
    Mitton CR;
    Can J Gastroenterol; 2002 Dec; 16(12):873-6. PubMed ID: 12522479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Technology assessment in Catalonia: integrating economic appraisal.
    Granados A; Borràs JM
    Soc Sci Med; 1994 Jun; 38(12):1643-6. PubMed ID: 8047922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.